Jul 14, 2026
With François Roubille, University Hospital Arnaud de
Villeneuve, Montpellier - France and Ruxandra Christodorescu,
University of Medicine and Pharmacy Victor Babes, Timisoara -
Romania.
In this podcast, François Roubille joins Ruxandra
Christodorescu to discuss inflammation and coronary artery
disease.
REFERENCES:
1. Ridker PM, Everett BM, Thuren T, et al; CANTOS Trial
Group. Antiinflammatory Therapy with Canakinumab for
Atherosclerotic Disease. N Engl J Med.
2017;377:1119-31. https://www.nejm.org/doi/10.1056/NEJMoa1707914
2. Tardif JC, Kouz S, Waters DD, et al. Efficacy and Safety
of Low-Dose Colchicine after Myocardial Infarction. N Engl J Med.
2019 Dec 26;381(26):2497-2505.
3. Nidorf SM, Fiolet ATL, Mosterd A, et al; LoDoCo2 Trial
Investigators. Colchicine in Patients with Chronic Coronary
Disease. N Engl J Med.;383:1838-1847.
4. Tardif JC, Kouz S. Efficacy and safety of colchicine and
spironolactone after myocardial infarction: the CLEAR-SYNERGY trial
in perspective. Eur Heart J Acute Cardiovasc Care.
2024;13:843-4. https://academic.oup.com/ehjacc/article/13/12/843/7906243
5. Byrne RA, Rossello X, Coughlan JJ, et al; ESC Scientific
Document Group. 2023 ESC Guidelines for the management of acute
coronary syndromes. Eur Heart J. 2023;44:3720-826. https://academic.oup.com/eurheartj/article/44/38/3720/7243210
6. Vrints C, Andreotti F, Koskinas KC, et al; ESC
Scientific Document Group. 2024 ESC Guidelines for the management
of chronic coronary syndromes. Eur Heart J.
2024;45:3415-3537. https://academic.oup.com/eurheartj/article/45/36/3415/7743115